This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe Spring

€500 savings end in:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
THE SPRINGTIME PARTNERING EVENT
March 18–20, 2024 | Barcelona, SpainMarch 26–27, 2024 | Digital Partnering

Ciloa

Profile

BIOENGINEERED EXOSOME PLATFORM FOR THERAPEUTIC AND PREVENTIVE SOLUTIONS
Ciloa is a French preclinical biotechnology company, spin-off from the CNRS and the University of Montpellier, with the world's leading experience in the development of exosome-based vaccines and therapeutic vectors. Ciloa has a unique patented technology for bioengineering exosomes with any functional protein at the membrane or in the cytosol. This technology is supported by a state-of-the-art in-house cleanroom manufacturing facility to produce GMP-like exosomes. The company operates as a highly versatile platform (ongoing collaborations with big pharma, big biotech and academia) that can tackle a wide range of inherited and acquired pathologies. Ciloa has developed a pipeline of biotherapeutic candidates for diabetes, metabolic, inflammatory and cardiovascular diseases, and oncology, as well as several vaccine candidates for emerging viral diseases. They are at various stages of development, from research to regulatory pre-clinical phases.Our lead candidate, the Adiponectin-Exosome, offers a new therapeutic approach to metabolic diseases by interfering with the origin of these pathologies, namely inflammation and oxidative stress. This approach has already proved its worth in animal models (DIO-NASH and DIO mice). It is now at the IND-enabling stage, and should be a "First in Human" therapeutic exosome in the clinic by 2025. This near-clinical exosome application has strong potential for success in commercially attractive therapeutic indications. We are looking for partners to develop and extend this innovative exosome product, enabling repeated, well-tolerated dosing to improve current treatments.In addition, our aim is to raise a Series A financing of € 18 M to finalize our activities, up to IND submission, and set up a Phase I clinical trial, while reinforcing the development of our platform.